ValenTx

About ValenTx

ValenTx, Inc. operates as a medical device company focused on developing treatments for morbid obesity and associated metabolic disorders like type 2 diabetes and hypertension. Founded in 2002 and headquartered in Maple Grove, Minnesota, the company has centered its efforts on creating a non-surgical, reversible alternative to traditional gastric bypass surgery.

The company's core product is the ValenTx endoluminal bypass therapy, an implantable and removable sleeve device. This therapy is designed to mimic the effects of Roux-en-Y gastric bypass surgery by attaching a sleeve to the gastroesophageal junction, which helps reduce food absorption. A key differentiator is that the device is implanted through a non-surgical, endoscopic procedure that does not require permanent anatomical changes or stapling. The device is also designed to be replaceable, allowing physicians to adjust the therapeutic profile to meet individual patient needs. The company serves patients with a Body Mass Index (BMI) between 35 and 50 who have not found success with non-surgical weight loss methods.

ValenTx has progressed through several stages of development, securing significant venture capital backing. Early investors included Sapient Capital, EDF Ventures, Kaiser Permanente, Affinity Capital Partners, and T-Gap Ventures. Over its lifetime, the company raised approximately $43.6 million in funding. Clinical trials have been a core part of its strategy, with studies designed to evaluate the safety, efficacy, and performance of the endo bypass system. A 2009 study involving 12 patients demonstrated an average excess weight loss of 39.5% over 12 weeks, and diabetic participants maintained normal fasting blood glucose levels without medication during the trial. Despite these trials, the device has not received FDA approval. The company's board has included experienced figures from the medical technology sector, such as former Boston Scientific COO Paul LaViolette and former Medtronic executive Bob Griffin. According to PitchBook data, the company is now listed as out of business as of January 2020.